United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components.

Pfizer Once Again the Most Shorted Dow Stock

Sanofi

SNY vs. PFE: Which Stock Is the Better Value Option?

CenturyLink

The stock charts of Pfizer, AES and Centurylink have emerged as enticing prospects within a sea of volatility.
The post 3 Big Stock Charts for Tuesday: Pfizer, AES and Centurylink appeared first on InvestorPlace.

3 Big Stock Charts for Tuesday: Pfizer, AES and Centurylink

AbbVie

Bristol-Myers

Johnson & Johnson

Merck

These five-star medicines should continue to push the industry higher in the next decade, despite the political blowback surrounding U.S. prescription drug prices.

These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024

Fitch Ratings downgraded Pfizer Inc.'s long-term issuer default rating by one notch to A from A-plus on Friday, after the closing of the acquisition of Array BioPharma earlier this week.

Fitch Ratings downgrades Pfizer to A vs. A-plus with negative outlook

Cisco Systems

Chevron

JPMorgan Chase & Co

Coca-Cola

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Exxon Mobil

The eight “Dogs of the Dow” have an aggregate year-to-date gain of 12.2%, lagging the Dow Jones Industrial Average, which is up 15.2%.

The 'Dogs Of The Dow' For 2019 Stalled In July

Apple

Amgen

Baker Hughes

Electronic Arts

Q2 earnings season rolls on and Wall Street tries to not act disappointed by the early end to the latest round of U.S.-China trade talks.

5 Stocks to Buy and Keep an Eye on Come Fall

Advanced Micro Devices

Options trading was buzzing in Pfizer, Advanced Micro Devices and Apple on Tuesday. Here are the metrics that matter moving forward.

Wednesday’s Vital Data: Pfizer, Advanced Micro Devices and Apple

The new company emerging from the Pfizer-Mylan deal gets former blockbusters like Lipitor and Celebrex, now generics, and the EpiPen business, which has been an object of scandal.
The post Here’s How Pfizer Stock (and Pharma) Stand to Benefit From Mylan Deal appeared first on InvestorPlace.

Here’s How Pfizer Stock (and Pharma) Stand to Benefit From Mylan Deal

Beyond Meat

McDermott

Sometimes even solid growth isn't enough to lift a stock's price.

Why Beyond Meat, McDermott International, and Pfizer Slumped Today

Capital One

Invitae

PepsiCo

Under Armour

Under Armour, PepsiCo, Invitae, Capital One and Pfizer are our top stock trades for Wednesday. Here's how to trade them.

5 Top Stock Trades for Wednesday (July 31)

The pharma giant beat EPS estimates but missed on revenue, with sales suffering from major drugs that are now offered as generics.

Pfizer Becomes a Falling Knife After Monday's Earnings

Morgan Stanley downgraded Pfizer Inc (NYSE: PFE) Tuesday after the drug company announced the spinoff of its Upjohn division on Monday, sending its stock downward.

Morgan Stanley Downgrades Pfizer In Wake Of Upjohn-Mylan Merger

Shares of Pfizer Inc. PFE, -5.30% tumbled 5.2% to pace the Dow Jones Industrial Average's DJIA, -0.18% decliners in morning trading Tuesday, after Bank of America Merrill Lynch analyst Jason Gerberry downgraded the drug maker in the wake of the deal in which the company's Upjohn business will merge with generic drugmaker Mylan N.V.

Pfizer's stock tumbles toward worst 2-day stretch in 10 1/2-years

Morgan Stanley downgraded Pfizer to equal-weight from overweight and slashed it price target to $40 per share from $48 per share.

Morgan Stanley downgrades Pfizer, says Mylan sale this week revealed some bad news

Mylan

Pfizer's proposed deal with Mylan is complicated. But if you're a Pfizer shareholder, here's what you need to know.

3 Key Things to Know About How the Mylan-Upjohn Merger Affects Pfizer Shareholders

Pfizer Inc. (PFE) CEO Albert Bourla on Q2 2019 Results - Earnings Call Transcript

Pfizer (NYSE:PFE) today announced its plan to combine its generic drugs business with Mylan in a Reverse Morris Trust transaction. The combined entity could generate sales of over $20 billion by 2020, and Pfizer will hold a 57% stake in the new company, with Mylan holding the rest.

How Big Is Pfizer's Generic Drugs Business That It Plans To Merge With Mylan?

No big surprises with Pfizer's Q2 earnings results. The big surprise was a major deal with Mylan that caused the results to be announced earlier than expected.

What You'll Want to Know About Pfizer's Q2 Earnings Results

Drugmaker Pfizer Inc. (NYSE:PFE) announced on Monday it is combining its off-patent drug business, which is called Upjohn, with Pittsburgh-based generic pharmaceutical giant Mylan NV (NASDAQ:MYL) in an all-stock deal, creating a new company.

Pfizer Inc to Combine Off-Patent Drug Business With Mylan NV

A new Mylan-Pfizer deal that will have the companies taking part in a merger agreement has MYL stock heading higher on Monday.
The post Mylan-Pfizer Deal: MYL Stock Soars on Off-Patent Drug Merger appeared first on InvestorPlace.

Mylan-Pfizer Deal: MYL Stock Soars on Off-Patent Drug Merger

Pfizer Inc  has agreed to spin off its off-patent branded drugs business and combine it with generic drugmaker Mylan NV , a move that leaves Pfizer with its more profitable innovative drugs, including cancer treatment Ibrance and pneumonia vaccine Prevnar.

Pfizer to spinoff, merge off-patent drugs unit with Mylan

Pfizer Inc. (NYSE: PFE) and Merck & Co. Inc. (NYSE: MRK) are each scheduled to release their second-quarter financial results before the markets open on Tuesday.

What to Watch When Merck and Pfizer Report Early on Tuesday

Pfizer Inc. is in talks to merge its contract manufacturer that produces Mylan’s EpiPen emergency allergy treatment into the new generics business it is creating by combining its older off-patent medicines unit with Mylan NV (MYL.O), a Pfizer spokeswoman said.

Pfizer in talks to transition EpiPen maker into generics spinoff: spokeswoman

Chipotle

Stocks were mixed on Wall Street Monday morning.

News for Pfizer Stock (PFE)